Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma

ErbB3 has been widely implicated in treatment resistance, but its role as a primary treatment target is less clear. Canonically ErbB3 requires EGFR or ErbB2 for activation, whereas these two established treatment targets are thought to signal independently of ErbB3. In this study, we show that ErbB3...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Redlich, Nathan, Robinson, Anthony M., Nickel, Kwangok P., Stein, Andrew P., Wheeler, Deric L., Adkins, Douglas R., Uppaluri, Ravindra, Kimple, Randall J., Van Tine, Brian A., Michel, Loren S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849045/
https://ncbi.nlm.nih.gov/pubmed/29305574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0029-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados